Miahelsa Holdings (7129) FY2026 Q3 Earnings Report

Quick View

Executive Summary

For the cumulative Q3 period, the Company secured increases in operating and ordinary income but fell into a net loss due to an impairment loss. Revenue was ¥18.41B (+4.0% YoY), operating income was ¥0.47B (+12.9%), and ordinary income was ¥0.47B (+15.4%), maintaining a trend of higher revenue and earnings. However, as an impairment loss of ¥0.37B related to assets used in the Pharmaceuticals Business was recorded as an extraordinary loss, the quarterly net loss attributable to owners of the parent was ¥0.04B, resulting in a shift to a loss from net income of ¥0.21B in the same period of the previous year. The fact that the operating income growth rate exceeded the revenue growth rate indicates signs of improved profitability, but final earnings were substantially impaired by a temporary factor.

Factors Affecting Results

【Revenue】Revenue was ¥18.41B, representing a +4.0% YoY increase. By segment, the Childcare Support Business posted the largest increase at ¥7.57B (+6.0%), while the Pharmaceuticals Business also secured higher revenue at ¥7.40B (+3.2%). The Nursing Care Business was nearly flat at ¥2.67B (-0.5%), and Other Businesses, including the Food Business, totaled ¥0.77B (+8.8%). The primary driver of revenue growth was the expansion of the Childcare Support Business, which led consolidated revenue growth.

【Profit and Loss】Operating income was ¥0.47B (+12.9% YoY), and ordinary income was ¥0.47B (+15.4%), achieving earnings growth above the revenue growth rate. The gross margin improved to 10.1% from 9.7% in the same period of the previous year, while the SG&A ratio also increased to 7.6% from 7.4%, absorbing part of the benefit from the gross margin improvement. Segment profit was driven by the Childcare Support Business at ¥0.82B (+12.8%), while the Pharmaceuticals Business declined to ¥0.34B (-15.6%). Against ordinary income of ¥0.47B, an extraordinary loss of ¥0.37B, including an impairment loss of ¥0.37B on assets used in the Pharmaceuticals Business, was recorded, compressing profit before tax to ¥0.10B. In addition, income taxes and other taxes of ¥0.14B exceeded profit before tax, resulting in an effective tax rate above 138% and a net loss of ¥0.04B. Despite higher revenue and earnings at the operating and ordinary income levels, the temporary impairment loss caused final earnings to turn negative, resulting in a conclusion of higher revenue and operating earnings but lower final earnings due to the extraordinary loss.

Segment Analysis

Total reported segment profit was limited to ¥1.22B (+2.7% YoY), while corporate expenses increased by +6.3% from ¥0.74B to ¥0.79B, restraining the growth of consolidated operating income. The Childcare Support Business generated segment profit of ¥0.82B, accounting for 65.4% of the total, and was the core, highly profitable business with a profit margin of 10.8%. Segment profit in the Pharmaceuticals Business declined to ¥0.34B (-15.6% YoY), with its profit margin falling to 4.5%; an impairment loss of ¥0.37B was recorded on assets used in this business. The Nursing Care Business improved its segment profit to ¥0.07B from ¥0.01B in the previous year, but its profit margin remained limited at 2.5%. While growth and improved profitability in the Childcare Support Business underpin consolidated earnings, the decline in asset profitability in the Pharmaceuticals Business remains a challenge.

Key Financial Indicators

【Profitability】The operating margin improved to 2.5% from 2.3% in the same period of the previous year, but the net profit margin was negative 0.2%, indicating that improvements at the operating level have not been reflected in final earnings.【Cash Flow Quality】Against ordinary income of ¥0.47B, profit before tax was compressed to ¥0.10B, and the non-recurring impairment loss of ¥0.37B significantly reduced earnings quality.【Investment Efficiency】Annualized ROE was negative 1.4%, primarily due to the deterioration in the net profit margin rather than deterioration in asset turnover or financial leverage.【Financial Soundness】The equity ratio was 28.2% (28.6% in the previous year), the current ratio was 94.6%, below 100%, and the total debt-to-equity ratio was high at 2.55x.

Cash Flow Analysis

Although detailed disclosure of the statement of cash flows is unavailable, an analysis of funding trends based on changes in the balance sheet shows that cash and deposits increased to ¥1.78B from ¥1.63B in the same period of the previous year. Meanwhile, short-term borrowings decreased by ¥0.40B from ¥1.20B to ¥0.80B, while long-term borrowings increased by ¥0.26B from ¥1.28B to ¥1.53B. This indicates a change in the capital structure involving reduced reliance on short-term borrowings while extending borrowing maturities. Property, plant and equipment decreased from ¥5.78B to ¥5.29B, suggesting the recognition of the impairment loss and restrained capital investment. Current liabilities of ¥6.11B exceeded current assets of ¥5.78B, indicating a situation that continues to require attention in working capital management.

Quality of Earnings

Ordinary income of ¥0.47B increased +15.4% YoY, reflecting improved earnings power in the core business. However, profit before tax was compressed to ¥0.10B due to the recognition of an extraordinary loss of ¥0.37B, creating a substantial divergence between ordinary income and net income. The primary extraordinary loss was the ¥0.37B impairment loss related to assets used in the Pharmaceuticals Business, a temporary factor equivalent to approximately 80% of cumulative operating income. An impairment loss of ¥0.22B was also recorded in the same period of the previous year, and the recognition of asset valuation losses for two consecutive periods suggests the need for ongoing verification of the asset profitability of the Pharmaceuticals Business. In addition, income taxes and other taxes of ¥0.14B exceeded profit before tax of ¥0.10B, resulting in an extremely high effective tax rate of above 138%. Comprehensive income was negative ¥0.04B, nearly in line with net income, indicating that the impact of valuation differences on available-for-sale securities and other items was minor. Overall, although earnings power at the operating and ordinary income levels has improved substantively, the quality of final earnings has been significantly impaired by temporary impairment losses and the tax burden.

Earnings Forecast and Guidance

Progress against the full-year Company plan was 74.8% for revenue, 72.8% for operating income, and 74.4% for ordinary income, generally close to the standard progress level as of Q3, approximately 75%. On the other hand, against the full-year net income plan of ¥0.25B, cumulative Q3 results were a net loss of ¥0.04B, requiring net income of at least approximately ¥0.29B in Q4 alone to achieve the plan. Operating and ordinary income are tracking broadly in line with the plan, but achieving the full-year net income target will require a significant recovery in Q4 earnings and the avoidance of additional one-time losses.

Shareholder Returns

A Q2 dividend of ¥13.00 per share has been paid, and the full-year dividend forecast is ¥30.00 (¥30.00 in the previous year). As the cumulative Q3 period resulted in a net loss, the payout ratio based on cumulative earnings is negative mathematically, and the dividend is not covered by cumulative earnings for the current period. Based on the Company’s full-year net income forecast of ¥0.25B, the forecast payout ratio is approximately 83.9%, exceeding 60%. Retained earnings of ¥2.55B provide a certain level of internal reserves as a source of dividends, but dividend sustainability will depend on earnings recovery in Q4 and the suppression of recurring impairment losses.

Risk Factors

1. Pharmaceuticals Business asset profitability risk: Although the Pharmaceuticals Business recorded revenue growth of +3.2%, segment profit declined -15.6% to ¥0.34B, and an impairment loss of ¥0.37B was recorded on assets used in the business. Impairment losses have been recorded for two consecutive periods, requiring close monitoring of the possibility of additional impairment.

2. Financial leverage and short-term liquidity: The total debt-to-equity ratio was 2.55x, while the current ratio was 94.6%, below 100%, with current assets below current liabilities. Interest-bearing debt of ¥2.33B is equivalent to 63.5% of equity of ¥3.67B, making the Company susceptible to interest-rate conditions and refinancing trends.

3. Increase in corporate expenses and pressure on profitability: Corporate expenses increased +6.3% YoY, exceeding the +4.0% revenue growth rate, and absorbed the difference between the +2.7% growth in total segment profit and the +12.9% growth in consolidated operating income. The effective tax rate was also high at above 138%, creating a structure in which fluctuations in profit before tax are likely to have an amplified impact on profit after tax.

Industry Benchmark (For Reference; Compiled by the Company)

Industry Benchmark (retail)

Profitability and Returns

The Company’s profitability is below the industry median for both metrics. In particular, the net profit margin is substantially below the industry median due to the impact of the impairment loss.

Growth and Capital Efficiency

The revenue growth rate is slightly above the industry median, but remains at a mid-range level compared with the upper bound of the industry IQR (10.3%).

※Source: Compiled by the Company

Key Takeaways from the Financial Results

1. While the trend of higher earnings in the core business continued, with operating income up +12.9% and ordinary income up +15.4%, the final result turned into a loss of ¥0.04B due to the ¥0.37B impairment loss on assets used in the Pharmaceuticals Business. A significant divergence between improvement at the operating level and final earnings is a defining feature of the current period.

2. The Childcare Support Business is the core of consolidated earnings, with revenue up +6.0% and segment profit up +12.8%, accounting for 65.4% of total segment profit. Profitability differences among the business portfolio are clearly evident: Childcare Support 10.8%, Pharmaceuticals 4.5%, and Nursing Care 2.5%.

3. Progress toward the full-year operating income plan was 72.8%, a standard level, but achieving the full-year net income plan of ¥0.25B will require a significant improvement in earnings in Q4. A current ratio of 94.6% and a total debt-to-equity ratio of 2.55x are financial indicators that should be monitored going forward.

Theoretical Share Price (Reference Value)

Sensitivity: ¥1,147–¥1,212 at ±1% for the cost of equity, and ¥1,174–¥1,181 at ±0.1 for ω.

Notes:

• Net income has been substantially compressed relative to operating income due to the tax burden, acquisition-related expenses, and non-controlling interests, among other factors (net income ÷ operating income 39%). This value reflects that compression at face value; if these factors are temporary, the underlying earnings power may be higher.
• Because forecast ROE is below the cost of equity, the theoretical value is below book value per share.
• Net assets as of the end of the quarter are used, resulting in a timing difference from the full-year forecast.
• Because net assets include non-controlling interests, the theoretical value may be calculated somewhat higher.

(Calculation model: Residual Income Model (Ohlson-type, explicit 5-year fade) / Interest rate reference month: 2026-07 / Mechanically calculated solely from publicly disclosed data; this is not a forecast of the market share price or a recommendation of any specific investment action, and does not predict or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings summary data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, after consulting professionals as necessary.

---End of Report---